Dr. Nallapareddy is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
22 W Dry Creek Cir
Littleton, CO 80120Phone+1 303-730-4700Fax+1 303-730-4790
Education & Training
- University of ColoradoFellowship, Hematology and Medical Oncology, 2006 - 2009
- University at BuffaloResidency, Internal Medicine, 2003 - 2006
- Osmania Medical College NTR UHSClass of 2000
Certifications & Licensure
- CO State Medical License 2007 - 2025
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Publications & Presentations
PubMed
- 16 citationsPhase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary c...Elizabeth R. Kessler, S. Gail Eckhardt, Todd M. Pitts, Erica L. Bradshaw-Pierce, Cindy L. O’byrant
Investigational New Drugs. 2016-04-01 - 13 citationsBiomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancerJohn J. Arcaroli, Kevin Quackenbush, Arvind Dasari, Rebecca W. Powell, Martine C. McManus
Cancer Medicine. 2012-10-01 - 415 citationsSafety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trialJeffrey R. Infante, Leslie A. Fecher, Gerald S. Falchook, Sujatha Nallapareddy, Michael S. Gordon
The Lancet. Oncology. 2012-08-01
Press Mentions
- OncLive® Hosts the Latest State of the Science Summit™ on Gastrointestinal MalignanciesMay 3rd, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: